Serapha Bio
Gene editing to cure alpha-1 antitrypsin deficiency
San Diego, United States · Founded 2026 · $138.0M raised
- Headquarters
- San Diego, California
- Employees
- 1–10
- Founded
- 2026
- Business Model
- B2B
- Website
- seraphabio.com
- Total Funding
- $138.0M
- Last Round
- $138.0M Series AJun 2026
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Serapha Bio is a gene-editing company developing treatments for alpha-1 antitrypsin deficiency (AATD) and other genetic diseases. The company has raised $138M and is advancing its pipeline through a merger with Boundless Bio alongside a $230M private placement.
Summary
Serapha Bio is a Biotech company based in San Diego, United States, founded in 2026. It has raised $138.0M in total across 1 round, most recently a $138.0M Series A round in Jun 2026. Investors include RA Capital Management and RTW Investments.
Funding History
Jun 2026
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/serapha-bio"><img src="https://indexed.vc/api/badge/company/serapha-bio" alt="Serapha Bio on Indexed.vc" width="260" height="76" /></a>